Here are four updates on the COVID-19 vaccine and antibody drugs from the past week:
The U.S. has given Merck a $356 million contract to supply up to 100,000 doses of an investigational drug that helped severe COVID-19 patients recover in clinical trials.
A Boston physician had a severe allergic reaction after receiving a COVID-19 vaccine from Moderna.
Novavax has started a phase 3 clinical trial for its COVID-19 vaccine candidate in the U.S.
Pfizer-BioNTech and Moderna's COVID-19 vaccines will likely hold up against the fast-spreading variant first detected in the U.K.